Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 26,
2018
Commission File Number: 001-37761
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its
charter.)
Nevada
(State or other jurisdiction of incorporation or
organization)
205093315
(IRS Employer Identification No.)
343 Allerton Avenue, South San Francisco, California
94080
(Address of principal executive offices)
650-577-3600
(Registrant's Telephone number)
Not Applicable
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2)
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. [
]
Item 2.02 Results of Operations and
Financial Condition.
See
Item 8.01.
Item 8.01
Other
Events.
On June
26, 2018, VistaGen Therapeutics, Inc. (the “Company”) issued a press release
to provide investors with a corporate update and to announce the
Company’s financial results for its fiscal year ended March
31, 2018. A copy of the press release is attached hereto as Exhibit
99.1.
The
information furnished herein and therein shall not be deemed
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that Section, or incorporated by
reference in any filing under the Exchange Act or the Securities
Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01 Financial Statements and
Exhibits.
See
Exhibit Index.
Disclaimer.
This
Current Report on Form 8-K may contain, among other things, certain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including, without
limitation, (i) statements with respect to the Company's plans,
objectives, expectations and intentions; and (ii) other statements
identified by words such as “may,” “could,”
“would,” “should,” “believes,”
“expects,” “anticipates,”
“estimates,” “intends,” “plans”
or similar expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
VistaGen
Therapeutics, Inc.
|
|
Date:
June 27, 2018
|
|
|
|
|
By:
|
/s/
Shawn K. Singh
|
|
|
Name:
Title:
|
Shawn
K. Singh
Chief
Executive Officer
|
EXHIBIT INDEX
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
|
Press
release issued by VistaGen Therapeutics, Inc. dated June 26,
2018.
|